A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Phase 3
600
about 6.4 years
6–17
20 sites in CT, FL, KY +9
What this study is about
This trial is testing the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine. Participants who previously completed studies for migraine are being offered a chance to continue taking eptinezumab.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Eptinezumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
eptinezumab
Primary: Number of Participants With Treatment Emergent Adverse Events
Secondary: Change From Baseline in Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS) Score at Weeks 12, 24, and 36
Neurology